EP1641486B1 - Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique - Google Patents

Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique Download PDF

Info

Publication number
EP1641486B1
EP1641486B1 EP04773889A EP04773889A EP1641486B1 EP 1641486 B1 EP1641486 B1 EP 1641486B1 EP 04773889 A EP04773889 A EP 04773889A EP 04773889 A EP04773889 A EP 04773889A EP 1641486 B1 EP1641486 B1 EP 1641486B1
Authority
EP
European Patent Office
Prior art keywords
erythropoietin
aqueous formulation
human erythropoietin
reagent
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04773889A
Other languages
German (de)
English (en)
Other versions
EP1641486A1 (fr
EP1641486A4 (fr
Inventor
Kyu Chan Kwon
Suk Young Choi
Young Cheol Kang
Hoon Sung Jeh
Seung Joo Lee
Myung Jin Kim
Ji Eon c/o LG Life Sciences Ltd. KIM
Jin-Seok c/o LG Life Sciences Ltd. Oh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1641486(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LG Life Sciences Ltd filed Critical LG Life Sciences Ltd
Publication of EP1641486A1 publication Critical patent/EP1641486A1/fr
Publication of EP1641486A4 publication Critical patent/EP1641486A4/fr
Application granted granted Critical
Publication of EP1641486B1 publication Critical patent/EP1641486B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to an aqueous formulation of human erythropoietin having the storage stability over a long period without serum albumin. More specifically, the present invention relates to the formulation comprising a pharmaceutically effective amount of human erythropoietin; non-ionic surfactant, polyhydric alcohol selected from the group consisting of propylene glycol and glycerol, neutral amino acid and sugar alcohol as stabilizers; isotonic reagent; and buffering reagent, wherein pH of the buffering reagent is in the range of 6.0 to 7.5.
  • Erythropoietin is a glycoprotein which induces production of erythrocytes in the bone marrow by stimulating differentiation of erythroid progenitor cells. EPO consists of 165 amino acids. After purification of erythropoietin from human urine by. Mijake in 1977, it has become possible to produce large amounts by genetic engineering technology. Erythropoietin was found to be able to induce effectively various hematopoiesis in the treatment of anemia resulting from a chronic renal insufficiency and various types of anemia by several causes, and in use during certain surgical procedures ( Mijake et al., J. Biol. Chem.
  • erythropoietin has been used as a pharmaceutical in various indications of diseases for a long time.
  • erythropoietin protein should also be carefully prepared to prevent denaturation from being caused by the loss of stability, for the purpose of the effective usage thereof.
  • proteins have a short half-life and denaturation easily occurs such as by aggregation of monomers, precipitation by aggregation, and adsorption to ampoule walls when exposed to extreme temperatures, interface of water and air, high pressure, physical and mechanical stresses, organic solvents, contamination by microorganisms and the like.
  • Denatured proteins lose their native physiochemical properties and physiological activity, and the denaturation of protein is generally irreversible. Thus, proteins cannot recover their native properties, once denatured.
  • proteins such as erythropoietin, which is administered in single dosages as small as a few micrograms, when they are adsorbed to the ampoule wall due to the disappearance of stability, the loss resulting therefrom is relatively considerable.
  • the protein thus adsorbed easily aggregates via a denaturation process, and administration of the denatured protein causes antibodies, as spontaneously produced proteins, to be formed against this denatured protein in a body, thus the protein should be administered in the substantially stable form.
  • various methods to prevent protein denaturation in aqueous solution have been studied ( John Geigert, J. Parenteral Sci. Tech, 43, No5, 220-224, 1989 ; David Wong, Pharm. Tech October, 34-48, 1997 ; Wei Wang, Int. J. Pharm., 1 85, 129-188, 1999 ; Willem Norde, Adv. Colloid Interface Sci., 25, 267-340, 1986 ; Michelle et al., Int. J. Pharm. 120, 179-188,1995 ).
  • Some protein formulations solved the denaturation with a lyophilization method.
  • lyophilized products are inconvenient since they have to be reconstituted prior to injection, and a large capacity freeze-dryer is required for processing, therefore, extensive investment is necessary.
  • a method of producing powdered forms of protein using spray-drying techniques is also used; however, it has disadvantages in that the economic efficiency decreases due to low yield and exposure to high temperature can cause protein denaturation during the process.
  • protein stabilizers there are known surfactants, serum albumin, polysaccharides, amino acids, macromolecules and salts ( John Geigert, J. Parenteral Sci. Tech., 43, No.5, 220-224, 1989 ; David Wong, Pharm. Tech., October, 34-48, 1997 ; Wei Wang., Int. J. Pharm., 185, 129-188, 1999 ).
  • suitable stabilizers should be selected in accordance with physiochemical characteristics of each protein; otherwise, for example, when stabilizers are used in certain combinations, competitive reaction or side reaction can occur to result in negative effects different from the intended effects. Moreover, since an appropriate range of concentrations exists for each stabilizer, much effort and caution are needed to stabilize aqueous proteins ( Wei Wang, Int. J. Pharm., 185, 129-188, 1999 ).
  • serum albumin and gelatin derived from human or animal
  • serum albumin and gelatin are generally used as stabilizers of aqueous protein formulations and have been proven to be effective.
  • gelatin and bovine serum albumin may transmit diseases like "Transmissible Spongiform Encephalopathies", or raise allergies in some patients; therefore, in Europe, use of materials from human and animal sources as pharmaceutical additives is increasingly restricted (EMEA/CPMP/BWP/450/10 Report from the Expert Workshop on Human TSEs and Medicinal products derived from Human Blood and Plasma (1 December 2000), CPMP/PS/201/98 Position Statement on New Variant CJD and Plasma-Derived Medicinal Products ( Superseded by CPMP / BWP / 2879 / 02 ).
  • WO 01/87329 A1 there are disclosed the aqueous formulations of erythropoietin and a multiple charged inorganic anion in a pharmaceutically acceptable buffer to keep the solution pH in the range from about pH 5.5 to about pH 7.0.
  • This application shows the comparative experiment regarding stability in which, after storage of EPO and PEGylated EPO at various temperatures for 6 months, the content of sialic acid and the standard bioactivity (%) of each EPO were measured in various formulations; however, since the amount of EPO monomers was not measured, the recovery yield (%) of EPO monomers cannot be precisely determined.
  • EP 0 909 564 discloses an erythropoietin solution preparation containing an amino acid as a stabiliser and having excellent long-term storage stability.
  • WO 00/61169 discloses an aqueous pharmaceutical formulations of erythropoietin that are free of human serum blood products, stabilised with the quantity of amino acid and a sorbiton mono-9-octadeconoate poly(oxo-1,2-ethanedyl) derivative.
  • the new aqueous formulation that has a long-term stability without using protein components derived from animal such as serum albumin.
  • the object of the present invention is to provide an aqueous formulation of erythropoietin which can maintain its biological activity over a long period in vivo without using serum albumin derived from human or animal.
  • erythropoietin preventing adhesion to the ampoule wall and protein denaturation, occurring upon storage for long periods, when a pharmaceutically effective amount of erythropoietin was combined with specific components as stabilizers, isotonic reagent and buffer reagent, and accomplished the invention.
  • the present invention provides the aqueous formulation of human erythropoietin without serum albumin, comprising a pharmaceutically effective amount of human erythropoietin; non-ionic surfactant, polyhydric alcohol selected from the group consisting of propylene glycol and glycerol, neutral amino acids, sugar alcohol as stabilizers; isotonic reagent; and buffering reagent, wherein pH of the buffering reagent is in the range of 6.0 to 7.5.
  • the human erythropoietin which can be used in the aqueous formulation of the present invention, includes every types of erythropoietin obtainable by isolation and purification from animal cells by native and/or genetic recombinant method.
  • the amount of the erythropoietin in the aqueous formulation is preferably 100 IU/ml to 120,000 IU/ml.
  • the aqueous formulation of the present invention contains the non-ionic surfactant to stabilize the formulation, thereby preventing adhesion to ampoule walls, in which the non-ionic surfactant decrease the surface tension of proteins to prevent adhesion or aggregation of the proteins on the hydrophobic surfaces.
  • the preferable example of non-ionic surfactant for use in the present invention includes polysorbate-based and poloxamer-based non-ionic surfactants, and they can be used alone or in combination of two or more thereof. Among them, polysorbate-based non-ionic surfactants are more preferable.
  • polysorbate 20 inhibits chemical degradation of protein, as well as decreasing or preventing the adhesion of proteins at low concentration, because its Critical Micelle Concentration is relatively low.
  • the use of high concentrations of the non-ionic surfactant in an aqueous formulation is not preferable because such concentration causes interference with UV-spectroscopy and Isoelectric Focusing in examining the stability and concentration of protein, so that it is difficult to evaluate protein stability. Therefore, in the aqueous formulation of the present invention, the non-ionic surfactant is preferably incorporated in amounts of less than 0.01%, more preferably 0.0001 to 0.01% (w/v).
  • the neutral amino acid allows more many water molecules to be present around erythropoietin so that the outermost hydrophilic amino acids of the erythropoietin can be stabilized, thereby stabilizing the erythropoietin itself ( Wang, Int. J. Pharm. 185 (1999) 129-188 ). Since charged amino acids can facilitate aggregation of erythropoietin by electrostatic interaction, the neutral amino acid is used in the aqueous formulation of the present invention.
  • the preferable example of neutral amino acid which can be used in the present invention, includes glycine, alanine, leucine, isoleucine, etc., and among them, glycine is more preferable.
  • neutral amino acid can be used alone or in combination with two or more; however, according to the experiments conducted by the inventors of the present invention, glycine is more effective when it is used alone than in combination with other amino acids.
  • the aqueous formulation of the present invention is not intended to be limited to using one kind of neutral amino acid.
  • the amount of neutral amino acid for use in the present invention is preferably 0.001 to 2% (w/v). If the amount is below this range, there may be no effect of increasing stability. On the other hand, if the amount is above this range, high concentration of erythropoietin cannot be achieved due to the increased osmotic pressure influencing solubility of erythropoietin.
  • the polyhydric alcohol is used as one of stabilizers for erythropoietin in the solution.
  • the polyhydric alcohol includes propylene glycol, glycerol, and one or a combination of two or more thereof. Especially among them, propylene glycol is more preferable.
  • Propylene glycol has been broadly used in pharmaceuticals administered via parenteral or non-parenteral routes as a solvent of hydrophobic materials, extractant and preservative, and it is considered as non-toxic. Furthermore, it is used as an emulsifier or vehicle in foods and cosmetics.
  • polypropylene glycol can also be used as a stabilizer of pharmaceuticals to increase the solubility of phospholipid when phospholipid is used as a stabilizer of the aqueous formulations.
  • Propylene glycol can also be used to increase the stability of aqueous formulations of protein, and it generally improves further the stability of aqueous formulations when used in combination with other stabilizers of suitable concentrations than when used alone.
  • the inventors of the present invention ascertained that, despite use of polypropylene glycol, the stability of aqueous formulation is unexpectedly decreased in case of not suitably selecting kinds and concentration ranges of other stabilizers which are used in combination with propylene glycol.
  • the amount of polyhydric alcohol is preferably 0.0001 to 0.1% (w/v). If the amount is below this range, there may be no effect of increasing stability. On the other hand, if the amount is above this range, there may be a problem with an increased osmotic pressure.
  • the sugar alcohol plays a role to stabilize erythropoietin when supplied in solution with the non-ionic surfactant, neutral amino acid and polyhydric alcohol as mentioned above.
  • the preferable example of the sugar alcohol includes mannitol, sorbitol, cyclitol, inositol, etc. which can be used alone or in combinations of two or more thereof. Among them, mannitol is more preferable.
  • the amount of the sugar alcohol is preferably 0.1 to 1.0% (w/v). If the amount is below this range, there may be no effect of increasing stability. On the other hand, if the amount is above this range, there may be a problem with an increased osmotic pressure.
  • Some stabilizers for example, sugar-alcohol and the like, are not limited to the literal meaning of term itself, but, in some cases, are also intended to take on other roles for preparation of aqueous formulation according to the present invention, for example, a role as isotonic reagent.
  • the isotonic reagent used as another component in the aqueous formulation of the present invention, serves to maintain the osmotic pressure when erythropoietin is administered into a body in the form of solution, and also has an additional effect of further stabilizing erythropoietin in the form of solution.
  • a representative example of isotonic reagent includes water-soluble inorganic salts, and these salts include, for example, sodium chloride, calcium chloride, sodium sulfate, etc. These salts can be used alone or in combinations of two or more thereof, and among them, sodium chloride is more preferable.
  • the amount of water-soluble inorganic salt is preferably 0.001 to 0.7% (w/v) and may be appropriately adjusted to allow the aqueous formulation, containing various components as described above, to be isotonic.
  • the buffering reagent serves to maintain pH of the solution for stabilization of erythropoietin.
  • the preferable example of the buffer reagent includes phosphate buffer, citrate buffer and the like, and among them, phosphate buffer is more preferable.
  • the concentration range of phosphate composing a phosphate buffer reagent is preferably between 5 ⁇ 50 mM and pH range of the solution is between about 6.0 ⁇ 7.5, with about 6.5 ⁇ 7.5 being more preferred.
  • any other substances or materials may be selectively contained, besides stabilizers, isotonic reagent and buffering reagent, within the range of not impairing the effects of the invention.
  • An isotonic solution was prepared by adding 0.003% polysorbate 20, 0.1% propylene glycol, 1.5% glycine, 0.1% sodium chloride and 1.0% mannitol to 10mM phosphate buffer solution, and erythropoietin (LG Life Science Co., Ltd.) was added to about 4000 IU/ml. 2 ml aliquots of the prepared solution were carefully transferred into a 3 ml glass vials and sealed, then stored at 25°C and 37°C, respectively.
  • COMPARATIVE EXAMPLE 1 REPARATION OF AQUEOUS FORMULATION OF HUMAN ERYTHROPOIETIN WITHOUT ADDTIVES
  • Erythropoietin was added in an amount of 4000 IU/ml into 10 mM phosphate buffer solution. 2 ml aliquots of the prepared solution were carefully transferred into a 3 ml glass vials and sealed, then stored at 25°C and 37°C, respectively.
  • COMPARATIVE EXAMPLE 2 PREPARATION OF AQUEOUS FORMULATION OF HUMAN ERYTHROPOIETIN CONTAINING ONLY POLYSORBATE 20
  • Erythropoietin was added in an amount of 4000 IU/ml into 10 mM phosphate buffer solution containing 0.003% polysorbate 20. 2 ml aliquots of the prepared solution were carefully transferred into a 3 ml glass vials and sealed, then stored at 25°C and 37° C, respectively.
  • COMPARATIVE EXAMPLE 3 PREPARATION OF AQUEOUS FORMULATION OF HUMAN ERYTHROPOIETIN WITHOUT PROPHYLENEGLYCOL
  • An isotonic solution was prepared by adding 0.003% polysorbate 20, 1.5% glycine, 0.1% sodium chloride and 1.0% mannitol to 10 mM phosphate buffer solution, and erythropoietin was added to about 4000 IU/ml. 2 ml aliquots of the prepared solution were carefully transferred into a 3 ml glass vials and sealed, then stored at 25°C and 37°C, respectively.
  • COMPARATIVE EXAMPLE 4 PREPARATION OF AQUEOUS FORMULATION OF HUMAN ERYTHROPOIETIN WITHOUT GLYCINE
  • An isotonic solution was prepared by adding 0.003% polysorbate 20, 0.5% propylene glycol, 0.1% sodium chloride and 1.0% mannitol to 10 mM phosphate buffer solution, and erythropoietin was added to about 4000 IU/ml. 2 ml aliquots of the prepared solution were carefully transferred into a 3 ml glass vials and sealed, then stored at 25°C and 37°C, respectively.
  • COMPARATIVE EXAMPLE 5 PREPARATION OF AQUEOUS FORMULATION OF HUMAN ERYTHROPOIETIN WITHOUT SODIUM CHLORIDE
  • An isotonic solution was prepared by adding 0.003% polysorbate 20, 1.7% glycine, 0.5% propylene glycol and 1.0% mannitol to 10 mM phosphate salt solution, and erythropoietin was added to about 4000 IU/ml. 2 ml aliquots of the prepared solution were carefully transferred into a 3 ml glass vials and sealed, then stored at 25°C and 37°C, respectively
  • COMPARATIVE EXAMPLE 6 PREPARATION OF AQUEOUS FORMULATION OF HUMAN ERYTHROPOIETIN WITHOUT MANNITOL
  • An isotonic solution was prepared by adding 0.003% polysorbate 20, 0.5% propylene glycol, 1.5% glycine and 0.1 % sodium chloride to 10 mM phosphate buffer solution, and erythropoietin was added to about 4000 IU/ml. 2 ml aliquots of the prepared solution were carefully transferred into a 3 ml glass vials and sealed, then stored at 37°C.
  • Example 1 as an aqueous formulation of erythropoietin according to the present invention, showed a recovery yield of more than 92% following storage for 5 weeks at 37°C, with no detection of dimers.
  • Comparative Example 2 containing only polysorbate 20 in the formulation, showed a high yield compared to addictive-free Comparative Example 1, but dimmers were detected.
  • Comparative Examples 3 to 6 not containing any one of components according to the present invention in the formulation, dimers were detected at 37°C, 3 weeks, and the recovery yield decreased to about 80%.
  • An isotonic solution was prepared by adding 0.01% polysorbate 20, 0.1% propylene glycol, 0.1% glycine, 0.55% sodium chloride and 1.0% mannitol to 10 mM phosphate buffer solution, and erythropoietin was added to about 4000 IU/ml. 0.5 ml aliquots of the prepared solution were collected into 1 ml pre-filled syringe (Becton-Dickinson) and stored at 40°C for 4 weeks.
  • COMPARATIVE EXAMPLE 7 PREPARATION OF AQUEOUS FORMULATION OF HUMAN ERYTHROPOIETIN WITHOUT PROPHYLENEGLYCOL AND MANNITOL
  • the formulation of the present invention showed a high recovery yield of 92.9% after incubation of 4 weeks, compared to 86.4% for the reference formulation.
  • the formulation of the present invention improves the stability of erythropoietin in solution.
  • aqueous formulations of TABLE 3 below differing in some components from the aqueous formulations in Example 1, were prepared and stored at 25°C and 37° C, respectively, under the same conditions as Example 1.
  • EPO 4000 IU/ml in PB 0.5% PVP 15K, 0.003% Tween 20, 1.5% Gly, 0.1 % NaCl,1 % Mannitol Com
  • EPO 4000 IU/ml in PB 0.5% PG, 0.003%, Tween 20, 1.5% Gly, 1mg/ml NaCl, 0.00001% Carboxymethylcellulose Com
  • PB phosphate buffer
  • PVP polyvinylpyrrolidone
  • the prepared solution was put into a glass vial and sealed, then stored at 37°C.
  • Comparative Example 14 which is an aqueous formulation of erythropoietin using polyethylene glycol as a polyhydric alcohol, has 97% recovery yield of monomers, and no dimmers are detected. This result differs greatly from the aqueous formulation of Comparative Example 3 not using polyhydric alcohol.
  • An isotonic solution was prepared by adding 0.003% polysorbate 20, 0.1% propylene glycol, 1.5% glycine, 1.0% mannitol and 0.1% sodium chloride to 10 mM phosphate buffer solution, and erythropoietin was added to about 12000 IU/ml. 0.5 ml aliquots of the prepared solution were collected into a 1 ml pre-filled syringe (Becton-Dickinson) and stored at 5°C, 25°C and 40°C for 3 months, respectively.
  • Becton-Dickinson Becton-Dickinson
  • the recovery yield and purity of the formulation prepared in Example 4 were determined after storage for 0, 6 and 12 months of storage at 5°C, and after storage for 2, 4 and 6 months at 25°C, and after storage for 1, 2 and 3 months at 40°C, respectively, using SEC-HPLC and RP-HPLC.
  • the degree of physiological activity was evaluated by administering the formulations into B6D2F1 mice, and measuring the increase of reticulocytes. The results are disclosed in TABLE 6 above.
  • the high concentration of erythropoetin in aqueous formulations showed the full recovery yield, purity and physiological activity until storage for 12 months at 5°C, and also until storage for 6 months at 25°C. Further, 94% of recovery yield was seen until storage for 3 months at 40°C, with little decrease in the purity and physiological activity. Therefore, the formulations according to Example 2 were confirmed to be very stable.
  • the aqueous formulation of erythropoietin according to the present invention containing human erythropoietin and non-ionic surfactant, polyhydric alcohol, neutral amino acid, sugar alcohol as a stabilizer, isotonic reagent and buffer reagent, improves the problem of decreased physiological activity due to denaturation upon long-term storage in solution; and in addition, has the effects of preventing erythropoietin proteins from adhering to ampoule walls.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Claims (11)

  1. Formulation aqueuse d'érythropoïétine humaine sans sérumalbumine, comprenant de l'érythropoïétine humaine ; un surfactant non ionique, un polyol choisi dans le groupe constitué de propylène glycol et de glycérol, un acide aminé neutre et un sucre-alcool en tant que stabilisants ; un réactif isotonique ; et un réactif tampon, où le pH du réactif tampon se situe dans la plage de 6,0 à 7,5.
  2. Formulation aqueuse d'érythropoïétine humaine selon la revendication 1, dans laquelle ladite érythropoïétine humaine est de l'érythropoïétine native ou recombinante.
  3. Formulation aqueuse d'érythropoïétine humaine selon la revendication 1, dans laquelle ledit surfactant non ionique est un surfactant non ionique à base de polysorbate ou un surfactant non ionique à base de poloxamère ou une combinaison de ceux-ci ;
    ledit acide aminé neutre est un ou plusieurs choisis dans le groupe constitué de glycine, alanine, leucine et isoleucine ;
    ledit sucre-alcool est un ou plusieurs choisis dans le groupe constitué de mannitol, sorbitol, cyclitol et inositol ;
    ledit réactif isotonique est un ou plusieurs choisis dans le groupe constitué de chlorure de sodium, chlorure de calcium et sulfate de sodium ; et
    ledit réactif tampon est un ou plusieurs choisis dans le groupe constitué d'un tampon phosphate et d'un tampon citrate.
  4. Formulation aqueuse d'érythropoïétine humaine selon la revendication 3, dans laquelle ledit surfactant non ionique est un polysorbate 20, et ledit polyol est le propylène glycol, et ledit acide aminé neutre est la glycine, et ledit sucre-alcool est le mannitol, et ledit réactif isotonique est le chlorure de sodium, et ledit réactif tampon est le tampon phosphate.
  5. Formulation aqueuse d'érythropoïétine humaine selon la revendication 1, dans laquelle la teneur en surfactant non ionique se situe dans la plage de 0,0001 à 0,01 % (p/v).
  6. Formulation aqueuse d'érythropoïétine humaine selon la revendication 1, dans laquelle la teneur en polyol se situe dans la plage de 0,001 à 0,1 % (p/v).
  7. Formulation aqueuse d'érythropoïétine humaine selon la revendication 1, dans laquelle la teneur en acide aminé neutre se situe dans la plage de 0,001 à 2 % (p/v).
  8. Formulation aqueuse d'érythropoiétine humaine selon la revendication 1, dans laquelle la teneur en sucre-alcool se situe dans la plage de 0,1 à 1,0 % (p/v).
  9. Formulation aqueuse d'érythropoïétine humaine selon la revendication 1, dans laquelle la teneur en dit réactif isotonique se situe dans la plage de 0,001 à 0,7 % (p/v).
  10. Formulation aqueuse d'érythropoïétine humaine selon la revendication 1, dans laquelle la concentration de sel dans le réactif tampon se situe dans la plage de 1 mM à 50 mM.
  11. Formulation aqueuse d'érythropoïétine humaine selon la revendication 1, dans laquelle la teneur en érythropoïétine se situe dans la plage de 100 UI/ml à 120 000 UI/ml.
EP04773889A 2003-06-10 2004-06-07 Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique Expired - Lifetime EP1641486B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20030037060 2003-06-10
PCT/KR2004/001358 WO2004108152A1 (fr) 2003-06-10 2004-06-07 Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique

Publications (3)

Publication Number Publication Date
EP1641486A1 EP1641486A1 (fr) 2006-04-05
EP1641486A4 EP1641486A4 (fr) 2008-10-08
EP1641486B1 true EP1641486B1 (fr) 2012-04-18

Family

ID=36337525

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04773889A Expired - Lifetime EP1641486B1 (fr) 2003-06-10 2004-06-07 Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique

Country Status (19)

Country Link
US (1) US8119595B2 (fr)
EP (1) EP1641486B1 (fr)
JP (1) JP4871720B2 (fr)
KR (1) KR100610003B1 (fr)
CN (1) CN1802171B (fr)
AT (1) ATE553747T1 (fr)
AU (1) AU2004244920B2 (fr)
BR (1) BRPI0411114B8 (fr)
CA (1) CA2528988C (fr)
EA (1) EA009676B1 (fr)
ES (1) ES2385888T3 (fr)
HK (1) HK1093012A1 (fr)
MX (1) MXPA05013398A (fr)
NO (1) NO20055747L (fr)
NZ (1) NZ543859A (fr)
PL (1) PL379272A1 (fr)
UA (1) UA82241C2 (fr)
WO (1) WO2004108152A1 (fr)
ZA (1) ZA200509222B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200640492A (en) 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
WO2007108505A1 (fr) 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha Préparation de solution d'érythropoïétine
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
EP3381445B1 (fr) 2007-11-15 2023-10-25 Amgen Inc. Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
MX2020005326A (es) * 2008-08-15 2022-03-03 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
MX2012008453A (es) * 2010-01-19 2012-11-21 Hanmi Science Co Ltd Formulaciones liquiddas para un conjugado de eritropoientina de accion prolongada.
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
ES2919136T3 (es) 2010-08-11 2022-07-22 Ironwood Pharmaceuticals Inc Formulaciones estables de linaclotida
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
US9708371B2 (en) 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2014160371A1 (fr) * 2013-03-13 2014-10-02 Eleven Biotherapeutics, Inc. Formulations de cytokine chimérique pour administration oculaire
EP2832361A1 (fr) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Compositions à libération prolongée aqueuse d'analogues de LHRH
US20180110833A1 (en) * 2015-04-21 2018-04-26 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
WO2023098844A1 (fr) * 2021-12-03 2023-06-08 杰科(天津)生物医药有限公司 Formulation, procédé de préparation s'y rapportant et son utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6191131A (ja) 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB9001987D0 (en) 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
WO1998034632A1 (fr) * 1997-02-07 1998-08-13 Emisphere Technologies, Inc. Composes et compositions destines a l'administration d'agents actifs
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
AU5649299A (en) * 1998-09-11 2000-04-03 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method for stabilizing the same
ES2308978T3 (es) * 1999-04-09 2008-12-16 Ortho-Mcneil Pharmaceutical, Inc. Composicion farmaceutica de eritropoyetina.
WO2001017542A1 (fr) * 1999-09-08 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Preparation de solution de proteines et procede de stabilisation associe
WO2001064241A1 (fr) * 2000-02-29 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees a long terme
ATE291436T2 (de) 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
SI21258A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol

Also Published As

Publication number Publication date
EP1641486A1 (fr) 2006-04-05
KR100610003B1 (ko) 2006-08-08
US20070293419A1 (en) 2007-12-20
EA200501789A1 (ru) 2006-06-30
EP1641486A4 (fr) 2008-10-08
ATE553747T1 (de) 2012-05-15
JP2007528842A (ja) 2007-10-18
NO20055747D0 (no) 2005-12-05
EA009676B1 (ru) 2008-02-28
KR20040110994A (ko) 2004-12-31
ZA200509222B (en) 2006-09-27
US8119595B2 (en) 2012-02-21
CA2528988A1 (fr) 2004-12-16
NO20055747L (no) 2006-03-07
BRPI0411114A (pt) 2006-07-18
AU2004244920B2 (en) 2009-07-23
PL379272A1 (pl) 2006-08-21
CA2528988C (fr) 2012-05-01
AU2004244920A1 (en) 2004-12-16
NZ543859A (en) 2008-01-31
ES2385888T3 (es) 2012-08-02
BRPI0411114B8 (pt) 2021-05-25
UA82241C2 (uk) 2008-03-25
HK1093012A1 (en) 2007-02-23
WO2004108152A1 (fr) 2004-12-16
JP4871720B2 (ja) 2012-02-08
CN1802171A (zh) 2006-07-12
BRPI0411114B1 (pt) 2020-09-15
MXPA05013398A (es) 2006-03-09
CN1802171B (zh) 2010-10-13

Similar Documents

Publication Publication Date Title
JP4683810B2 (ja) 長期安定化製剤
JP3068033B2 (ja) エリスロポエチン溶液製剤
CA2780554C (fr) Preparation pour combinaison d'hormones de croissance humaine (hgh) et de rhigf-1
EP1641486B1 (fr) Solutions aqueuses stables d'erythropoietine humaine ne contenant pas d'albumine serique
HU202761B (en) Process for producing stabilized erythropoietin compositions
JP4119407B2 (ja) 凍結乾燥されたアルブミン非含有の組換え人血液凝固第8因子製剤
EP0612530A2 (fr) Préparations pharmazeutiques qui contiennent le facteur cytotoxique tumoral
US20170360891A1 (en) Stable, Benzyl Alcohol-free Aqueous Solution Formulations Containing Alpha-type Interferon
EP1689437B1 (fr) Formulation d'une solution d'erythropoietine
KR20180049887A (ko) 페길레이션된 에리스로포이에틴을 포함하는 신규한 제제
MXPA06005791A (en) Erythropoietin solution formulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAX Requested extension states of the european patent have changed

Extension state: AL

Payment date: 20051214

Extension state: LV

Payment date: 20051214

Extension state: MK

Payment date: 20051214

Extension state: LT

Payment date: 20051214

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1093012

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20080904

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/08 20060101AFI20080829BHEP

Ipc: A61K 47/18 20060101ALI20080829BHEP

Ipc: A61K 47/10 20060101ALI20080829BHEP

Ipc: A61K 47/12 20060101ALI20080829BHEP

Ipc: A61K 47/02 20060101ALI20080829BHEP

Ipc: A61K 38/18 20060101ALI20080829BHEP

Ipc: A61K 47/26 20060101ALI20080829BHEP

17Q First examination report despatched

Effective date: 20090219

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 553747

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004037442

Country of ref document: DE

Effective date: 20120621

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2385888

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120802

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120418

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1093012

Country of ref document: HK

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 553747

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120418

LTLA Lt: lapse of european patent or patent extension
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120820

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120719

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120630

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120418

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130121

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120607

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120630

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004037442

Country of ref document: DE

Effective date: 20130121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120718

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040607

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20140312

Year of fee payment: 11

Ref country code: ES

Payment date: 20140403

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004037442

Country of ref document: DE

Representative=s name: PATENTANWAELTE WEICKMANN & WEICKMANN, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004037442

Country of ref document: DE

Representative=s name: WEICKMANN & WEICKMANN PATENTANWAELTE - RECHTSA, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004037442

Country of ref document: DE

Representative=s name: WEICKMANN & WEICKMANN PATENT- UND RECHTSANWAEL, DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004037442

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160101

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150608

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20171102 AND 20171108

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: LG CHEM, LTD., KR

Effective date: 20171208

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230523

Year of fee payment: 20

Ref country code: FR

Payment date: 20230522

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230525

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230523

Year of fee payment: 20